TCIC-001

TCIC-001 is an investigational drug developed by Thomson Biotech (Xiamen) for use as a bowel preparation agent in patients scheduled for colonoscopy. It is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, efficacy, and pharmacokinetics when used for intestinal preparation prior to colonoscopic procedures. The primary objective of these studies is to determine the optimal dosing regimen and establish preliminary evidence of effectiveness and pharmacokinetic profile in this setting. The specific molecular composition, mechanism of action, and modality have not been publicly disclosed as of June 2025[1][7].